Pipex Pharmaceuticals (PP) sounds like a scam outfit. On today’s CC, management hyped the “drug” for dry AMD, which is a non-starter, IMO (#msg-21105688).
Then they said Lucentis is selling $2B per year, which is a complete fabrication (and irrelevant because Lucentis does not treat dry AMD).
Caveat emptor.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”